Amlodipine increases risk of primary open-angle glaucoma

The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken...

Full description

Saved in:
Bibliographic Details
Published inClinical hypertension Vol. 30; no. 1; p. 33
Main Authors Lehrer, Steven, Rheinstein, Peter H.
Format Journal Article
LanguageEnglish
Published England BioMed Central 01.11.2024
대한고혈압학회
Subjects
Online AccessGet full text

Cover

Loading…
Abstract The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed. We used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma. Amlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% (P = 0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine. Amlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG. None.
AbstractList The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed.We used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma. Amlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% ( P  = 0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine. Amlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG.None. Background The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed. Methods We used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma. Results Amlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% (P=0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine. Conclusions Amlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG. KCI Citation Count: 0
The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed.BACKGROUNDThe use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed.We used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma.METHODSWe used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma.Amlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% (P = 0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine.RESULTSAmlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% (P = 0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine.Amlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG.CONCLUSIONSAmlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG.None.TRIAL REGISTRATIONNone.
BackgroundThe use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed.MethodsWe used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma.ResultsAmlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% (P = 0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine.ConclusionsAmlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG.Trial registrationNone.
The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who had received calcium channel blocker medication were at a 23% increased risk of developing glaucoma in comparison to those who had never taken the antihypertensive drugs. We wished to confirm this association and examine POAG genes that might be involved, since the genetics has not yet been analyzed. We used MedWatch and UK Biobank data to evaluate the effects of amlodipine on POAG and intraocular pressure (IOP). We analyzed three POAG-associated single-nucleotide polymorphisms: rs9913911, an intron variant in growth arrest-specific 7 (GAS7), one of the genes that influences IOP; rs944801, an intron variant within CDKN2B-AS1, and rs2093210, an intron variant within SIX6, known to be associated with vertical cup-disc ratio, an important optic nerve head parameter that is often used to define or diagnose glaucoma. Amlodipine use in MedWatch doubled the prevalence of POAG, from 0.0805 to 0.177%, a small but significant increase. Multivariate analysis by logistic regression of UK Biobank data revealed that POAG risk was significantly increased with age, male sex, major alleles of rs9913911 (GAS7) and rs944801 (CDKN2B-AS1), and minor allele of rs2093210 (SIX6). Amlodipine increased POAG risk by 16.1% (P = 0.032). Amlodipine has not been associated with increased IOP. We confirmed this lack of association and in addition found that GAS7, associated with IOP, was not associated with POAG risk and amlodipine. But CDKN2B-AS1 and SIX6, POAG genes not associated with IOP, were associated with POAG and amlodipine. Amlodipine, a frequently prescribed drug and first line treatment for hypertension, has a potentially hazardous relationship with POAG. Knowledge of this link can guide the prescribing of alternate drugs for hypertensive individuals who have glaucoma or are at risk for it. Diuretics and β-blockers are not associated with POAG or increased IOP and could be substituted for amlodipine in hypertensive patients at risk POAG. None.
Author Rheinstein, Peter H.
Lehrer, Steven
Author_xml – sequence: 1
  givenname: Steven
  orcidid: 0000-0002-4850-094X
  surname: Lehrer
  fullname: Lehrer, Steven
  organization: Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY USA
– sequence: 2
  givenname: Peter H.
  surname: Rheinstein
  fullname: Rheinstein, Peter H.
  organization: Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39482785$$D View this record in MEDLINE/PubMed
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003134795$$DAccess content in National Research Foundation of Korea (NRF)
BookMark eNp9kUtLBDEQhIMovv-ABxnwIsJo5znJcRFfIAii55DJZpa4M8mazBz890Z3BfHgqfvwVdFddYC2QwwOoRMMlxhLcZUZSMlrIKwGIApqtYX2CXBRcwVq-9e-h45zfgMAzLlSIHbRHlVMkkbyfSRnQx_nfuWDq3ywyZnscpV8Xlaxq1bJDyZ9VHHlQm3ConfVojeTjYM5Qjud6bM73sxD9Hp783J9Xz8-3T1czx5ryzCMNWG8cY3ApJPccMdaxuaiVdZxKhSbd0ZCqygxWFpguG2xI9A1naEcW4mFoYfoYu0bUqeX1uto_PdcRL1Mevb88qAxCEYajgt8voZXKb5PLo968Nm6vjfBxSlrigmFhlMmCnr2B32LUwrlFU1JiUow1dBCnW6oqR3cXG8C0T8BFkCuAZtizsl12vrRjD6GMRnfl9P0V116XZcudenvurQqUvJH-uP-j-gTUEWTxg
CitedBy_id crossref_primary_10_7759_cureus_74976
Cites_doi 10.1186/s13742-015-0047-8
10.2165/11204420-000000000-00000
10.1093/function/zqad047
10.1016/S0140-6736(13)61752-3
10.1371/journal.pgen.1002611
10.2165/00002018-200730060-00009
10.1016/j.ophtha.2023.05.001
10.1186/s13041-016-0238-y
10.1001/jama.1993.03500210065033
10.1001/jamaophthalmol.2023.3877
10.1038/s41588-018-0176-y
10.1038/s41433-019-0603-z
10.1111/j.1360-0443.2009.02504.x
10.1016/j.ophtha.2018.01.007
10.1136/bjo.2004.053397
10.1097/IJG.0000000000001118
10.1007/s40264-015-0333-5
10.1007/s11682-021-00548-y
10.1093/jnci/djz241
10.1016/j.ophtha.2015.11.031
10.1038/nbt.2113
10.1167/iovs.61.11.25
10.1002/pds.677
10.1371/journal.pone.0157753
ContentType Journal Article
Copyright 2024. The Author(s).
2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2024. The Author(s).
– notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
7X8
ACYCR
DOI 10.1186/s40885-024-00290-9
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials - QC
ProQuest Central Database Suite (ProQuest)
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
Korean Citation Index
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE - Academic
Publicly Available Content Database
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2056-5909
EndPage 33
ExternalDocumentID oai_kci_go_kr_ARTI_10642751
39482785
10_1186_s40885_024_00290_9
Genre Journal Article
GeographicLocations United Kingdom--UK
United States--US
GeographicLocations_xml – name: United Kingdom--UK
– name: United States--US
GroupedDBID 0R~
5-W
5VS
8JR
AAFWJ
AAYXX
ACGFS
ADBBV
ADRAZ
ADUKV
AFPKN
AHBYD
AHSBF
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
ASPBG
BAWUL
BCNDV
BFQNJ
BMC
C6C
CITATION
DIK
EBS
EF.
EJD
GROUPED_DOAJ
H13
HYE
IAO
IHR
IHW
ITC
KQ8
M48
M~E
OK1
PGMZT
RBZ
ROL
RPM
RSV
SOJ
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AHMBA
ALIPV
AZQEC
BENPR
BPHCQ
BVXVI
CCPQU
DWQXO
FYUFA
HMCUK
K9.
MOJWN
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PROAC
UKHRP
7X8
ACYCR
ID FETCH-LOGICAL-c410t-2457e7612f85a5e4b44d6b9ce53694dfa80b932a18c041bb1e20f7fa351c816a3
IEDL.DBID 7X7
ISSN 2056-5909
1342-2154
2635-6325
IngestDate Thu Jul 24 03:28:46 EDT 2025
Fri Jul 11 03:20:12 EDT 2025
Mon Jun 30 10:54:07 EDT 2025
Mon Jul 21 06:02:24 EDT 2025
Sun Jul 06 05:07:11 EDT 2025
Thu Apr 24 23:10:13 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Glaucoma
Systemic medication
Epidemiology
Intraocular pressure
Language English
License 2024. The Author(s).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c410t-2457e7612f85a5e4b44d6b9ce53694dfa80b932a18c041bb1e20f7fa351c816a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
https://clinicalhypertension.biomedcentral.com/articles/10.1186/s40885-024-00290-9
ORCID 0000-0002-4850-094X
OpenAccessLink https://www.proquest.com/docview/3201564973?pq-origsite=%requestingapplication%
PMID 39482785
PQID 3201564973
PQPubID 2040145
PageCount 1
ParticipantIDs nrf_kci_oai_kci_go_kr_ARTI_10642751
proquest_miscellaneous_3123075346
proquest_journals_3201564973
pubmed_primary_39482785
crossref_citationtrail_10_1186_s40885_024_00290_9
crossref_primary_10_1186_s40885_024_00290_9
PublicationCentury 2000
PublicationDate 2024-11-01
PublicationDateYYYYMMDD 2024-11-01
PublicationDate_xml – month: 11
  year: 2024
  text: 2024-11-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Clinical hypertension
PublicationTitleAlternate Clin Hypertens
PublicationYear 2024
Publisher BioMed Central
대한고혈압학회
Publisher_xml – name: BioMed Central
– name: 대한고혈압학회
References van Koolwijk (10.1186/s40885-024-00290-9_ref17) 2012; 8
Arthur (10.1186/s40885-024-00290-9_ref12) 2020; 112
Zhang (10.1186/s40885-024-00290-9_ref20) 2016; 9
Curran (10.1186/s40885-024-00290-9_ref3) 2010; 70
Agrawal (10.1186/s40885-024-00290-9_ref18) 2009; 104
Böhm (10.1186/s40885-024-00290-9_ref8) 2012; 30
Kessler (10.1186/s40885-024-00290-9_ref6) 1993; 269
Zheng (10.1186/s40885-024-00290-9_ref24) 2018; 125
Böhm (10.1186/s40885-024-00290-9_ref9) 2016; 11
Lawrence (10.1186/s40885-024-00290-9_ref16) 2021; 15
Chan (10.1186/s40885-024-00290-9_ref14) 2016; 123
Chang (10.1186/s40885-024-00290-9_ref15) 2015; 4
10.1186/s40885-024-00290-9_ref4
Wu (10.1186/s40885-024-00290-9_ref23) 2020; 34
Lehrer (10.1186/s40885-024-00290-9_ref19) 2022; 14
Hauben (10.1186/s40885-024-00290-9_ref27) 2007; 30
Evans (10.1186/s40885-024-00290-9_ref11) 2001; 10
Mahmood (10.1186/s40885-024-00290-9_ref13) 2014; 383
Vergroesen (10.1186/s40885-024-00290-9_ref1) 2023; 130
Lehrer (10.1186/s40885-024-00290-9_ref7) 2019; 28
Langman (10.1186/s40885-024-00290-9_ref26) 2005; 89
Kastner (10.1186/s40885-024-00290-9_ref22) 2023; 141
Asefa (10.1186/s40885-024-00290-9_ref25) 2020; 61
Coloma (10.1186/s40885-024-00290-9_ref10) 2015; 38
Bird (10.1186/s40885-024-00290-9_ref5) 2023; 4
MacGregor (10.1186/s40885-024-00290-9_ref21) 2018; 50
Khawaja (10.1186/s40885-024-00290-9_ref2) 2019; 28
References_xml – volume: 4
  start-page: 7
  year: 2015
  ident: 10.1186/s40885-024-00290-9_ref15
  publication-title: Gigascience
  doi: 10.1186/s13742-015-0047-8
– volume: 70
  start-page: 191
  year: 2010
  ident: 10.1186/s40885-024-00290-9_ref3
  publication-title: Drugs
  doi: 10.2165/11204420-000000000-00000
– volume: 4
  start-page: zqad047
  year: 2023
  ident: 10.1186/s40885-024-00290-9_ref5
  publication-title: Function (Oxf)
  doi: 10.1093/function/zqad047
– volume: 383
  start-page: 999
  year: 2014
  ident: 10.1186/s40885-024-00290-9_ref13
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)61752-3
– volume: 8
  start-page: e1002611
  year: 2012
  ident: 10.1186/s40885-024-00290-9_ref17
  publication-title: PLoS Genet
  doi: 10.1371/journal.pgen.1002611
– volume: 30
  start-page: 551
  year: 2007
  ident: 10.1186/s40885-024-00290-9_ref27
  publication-title: Drug Saf
  doi: 10.2165/00002018-200730060-00009
– volume: 130
  start-page: 893
  year: 2023
  ident: 10.1186/s40885-024-00290-9_ref1
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2023.05.001
– volume: 9
  start-page: 54
  year: 2016
  ident: 10.1186/s40885-024-00290-9_ref20
  publication-title: Mol Brain
  doi: 10.1186/s13041-016-0238-y
– volume: 269
  start-page: 2765
  year: 1993
  ident: 10.1186/s40885-024-00290-9_ref6
  publication-title: JAMA
  doi: 10.1001/jama.1993.03500210065033
– volume: 141
  start-page: 956
  year: 2023
  ident: 10.1186/s40885-024-00290-9_ref22
  publication-title: JAMA Ophthalmol
  doi: 10.1001/jamaophthalmol.2023.3877
– volume: 50
  start-page: 1067
  year: 2018
  ident: 10.1186/s40885-024-00290-9_ref21
  publication-title: Nat Genet
  doi: 10.1038/s41588-018-0176-y
– volume: 34
  start-page: 12
  year: 2020
  ident: 10.1186/s40885-024-00290-9_ref23
  publication-title: Eye (Lond)
  doi: 10.1038/s41433-019-0603-z
– volume: 104
  start-page: 518
  year: 2009
  ident: 10.1186/s40885-024-00290-9_ref18
  publication-title: Addiction
  doi: 10.1111/j.1360-0443.2009.02504.x
– volume: 125
  start-page: 984
  year: 2018
  ident: 10.1186/s40885-024-00290-9_ref24
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2018.01.007
– volume: 89
  start-page: 960
  year: 2005
  ident: 10.1186/s40885-024-00290-9_ref26
  publication-title: Br J Ophthalmol
  doi: 10.1136/bjo.2004.053397
– volume: 28
  start-page: 205
  year: 2019
  ident: 10.1186/s40885-024-00290-9_ref7
  publication-title: Discov Med
– volume: 28
  start-page: e49
  year: 2019
  ident: 10.1186/s40885-024-00290-9_ref2
  publication-title: J Glaucoma
  doi: 10.1097/IJG.0000000000001118
– volume: 38
  start-page: 921
  year: 2015
  ident: 10.1186/s40885-024-00290-9_ref10
  publication-title: Drug Saf
  doi: 10.1007/s40264-015-0333-5
– volume: 15
  start-page: 2813
  year: 2021
  ident: 10.1186/s40885-024-00290-9_ref16
  publication-title: Brain Imaging Behav
  doi: 10.1007/s11682-021-00548-y
– volume: 112
  start-page: 893
  year: 2020
  ident: 10.1186/s40885-024-00290-9_ref12
  publication-title: J Natl Cancer Inst
  doi: 10.1093/jnci/djz241
– volume: 123
  start-page: 771
  year: 2016
  ident: 10.1186/s40885-024-00290-9_ref14
  publication-title: Ophthalmology
  doi: 10.1016/j.ophtha.2015.11.031
– volume: 30
  start-page: 137
  year: 2012
  ident: 10.1186/s40885-024-00290-9_ref8
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.2113
– volume: 61
  start-page: 25
  year: 2020
  ident: 10.1186/s40885-024-00290-9_ref25
  publication-title: Invest Ophthalmol Vis Sci
  doi: 10.1167/iovs.61.11.25
– ident: 10.1186/s40885-024-00290-9_ref4
– volume: 10
  start-page: 483
  year: 2001
  ident: 10.1186/s40885-024-00290-9_ref11
  publication-title: Pharmacoepidemiol Drug Saf
  doi: 10.1002/pds.677
– volume: 14
  start-page: e23919
  year: 2022
  ident: 10.1186/s40885-024-00290-9_ref19
  publication-title: Cureus
– volume: 11
  start-page: e0157753
  year: 2016
  ident: 10.1186/s40885-024-00290-9_ref9
  publication-title: PLoS ONE
  doi: 10.1371/journal.pone.0157753
SSID ssj0001559906
ssj0001853425
ssib042018900
Score 2.273089
Snippet The use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general, those who...
BackgroundThe use of calcium channel blockers is associated with primary open-angle glaucoma (POAG) in a statistically meaningful but minor way. In general,...
SourceID nrf
proquest
pubmed
crossref
SourceType Open Website
Aggregation Database
Index Database
Enrichment Source
StartPage 33
SubjectTerms Biobanks
Chromosomes
Cornea
FDA approval
Genomes
Glaucoma
Optic nerve
내과학
SummonAdditionalLinks – databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LS-RAEC5GhWUv4nONLyLrTXpNT7qT7oOIiIMKsycHvDWdpFvEMdF5gP57q_IYEHTZUw7patL1SH1FdVUBHFPHk9xqiUEOtwyVQqLNiZQlhbXOS2-FoELh4d_keiRu7-V9D7pxRy0Dp1-GdjRPajQZ_3l7fT9Hgz-rDV4lp1OBpkJ1xoJRkilieglW0DOlZKjDFu43VcMSf771vDn0-0zqSHd1NF9u88lXLZUT_z0Mrd3RYA1WWxwZXjSCX4eeKzfgx7DNlG-CungeVwUNpnbhY0nQcOqmIV0kDysfvjQ9JkI6K7Plw9iFCKPnqH12C0aDq7vLa9ZOSWC54NGM9YVMXYpAxStppROZEEWS6dzJONGi8FZFGYI0y1UeCZ5l3PUjn3obS54rnth4G5bLqnQ7EGplU1nwDENCKZBaeZRWkSPkKwrEOVEAvOOHydsW4jTJYmzqUEIlpuGhQR6amodGB3CyoGkP98_Vv5HN5il_NNT3mp4PlXmaGET3N0iH0VIqeQD7nRhMpzEm7lNVuNBpHMDR4jUaC2VAbOmqOa7hdO9dxiIJ4FcjvsVHxZo6oiq5-x_Ue_CzT3pS1yTuw_JsMncHCE5m2WGtcR-3y9n4
  priority: 102
  providerName: Scholars Portal
Title Amlodipine increases risk of primary open-angle glaucoma
URI https://www.ncbi.nlm.nih.gov/pubmed/39482785
https://www.proquest.com/docview/3201564973
https://www.proquest.com/docview/3123075346
https://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART003134795
Volume 30
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
ispartofPNX Clinical Hypertension, 2024, 30(0), , pp.33-33
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT9wwEB4VuPRSteorLV2lam-VRbwZx84JQQWilUAVKtKqF8vxAyGWhG52_z8z2eyiHsrFOcSO4nnY39jzAPjKGU-8qxUZOdIJEgpFOodaVMG5mFRyiBwofH5RnV3hz5majQdu_ehWuVkTh4U6dJ7PyA_KKQf9Yq3Lw_u_gqtG8e3qWEJjB_Y4dRm7dOmZfjxjob0Ih7qrsuQoFIILm7gZUx30SBrG4cko-G6qEPU_e9NOu0j_h53D9nP6El6MuDE_WjP6FTyL7WswR3fzLnD16ZjftIz_-tjn7C2edym_XyeSyLlAlnDt9TzmhJVXNF33Bq5OT35_PxNjKQThURZLMUWloyY0koxyKmKDGKqm9lGVVY0hOVM0hMScNL5A2TQyToukkyuV9EZWrnwLu23XxveQ18ZpFWRDdp9CGm0SsSR4wnUhEJgpMpAbIlg_5gnnchVzO9gLprJrwlkinB0IZ-sMvm3HjJN7svcXoq299TeWk1vz87qztwtLEP4HjSOTSCuZwf6G9nbUq94-SkEGn7evSSP4msO1sVtRH8nO7cT5KoN3a55tf6qsOe2pUR-e_vhHeD5luRhiDvdhd7lYxU8EPpbNZJCwCewdn1z8upwMJjy152iovTz-8wAs49Xu
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Nb9QwEB212wNcEBVfKaUYAScUNU7sxDmgqkCrXdquEGql3oxjO1XVJSmbXSH-FL-xM_nYigO99ZRDbCt5Htvv2Z4ZgHcU8cSaXKLI4SZEo5A45kQWps4YX8rSCEGOwifTdHwmvp7L8zX4O_jC0LXKYU5sJ2pXW9oj301icvoVeZbsXf8KKWsUna4OKTQ6szjyf36jZGs-Tr5g_76P48OD08_jsM8qEFrBo0UYC5l5FO9xqaSRXhRCuLTIrZdJmgtXGhUVSGoMVzYSvCi4j6MyK00iuVU8NQm2uw4bIkEpM4KNTwfTb99vd3Vw9RNtpleekN8LEpTBU0elu43AMU0O0SKk07AozP9ZDderefl_otsueIeP4VHPVNl-Z1qbsOarJ6D2f85qR_muPbusiHE2vmF0P53VJbvuQlcwSskVmupi5hmy8yUCbJ7C2b3A9AxGVV35F8ByZTLpeIFKUyJsuSrRCJxFJukc0qcoAD6AoG0fmZwSZMx0q1BUqjvgNAKnW-B0HsCHVZ3-5-4s_Rax1Vf2UlM4bXpe1PpqrlE0TLAeirBM8gC2B-x1P5IbfWt3AbxZvcYxSAcrpvL1Estwuk6PPZ8G8Lzrs9VHJTkFWlVy6-7GX8OD8enJsT6eTI9ewsOYbKT1eNyG0WK-9K-Q-iyKnd7eGPy4bxO_AflwDwo
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Amlodipine+increases+risk+of+primary+open-angle+glaucoma&rft.jtitle=Rinsh%C5%8D+k%C5%8Dketsuatsu+%3D+Clinical+hypertension&rft.au=Lehrer%2C+Steven&rft.au=Rheinstein%2C+Peter+H&rft.date=2024-11-01&rft.pub=BioMed+Central&rft.issn=1342-2154&rft.volume=30&rft.spage=1&rft_id=info:doi/10.1186%2Fs40885-024-00290-9
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2056-5909&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2056-5909&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2056-5909&client=summon